Be Bio’s New $130m Raise Will Advance B-Cell Therapies Toward The Clinic

 
• By Joseph Haas
  
B cells
Be Bio aims to bring engineered b-cell therapies to cancer and rare disease patients • Source: Alamy
Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

SpotifyApple PodcastsWebsite

More from Financing

More from Business